Warning! GuruFocus detected
1 Medium warning sign
with BCAX.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Bicara Therapeutics Inc
NAICS : 541715
SIC : 2833
ISIN : US0554771032
Description
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1170.24 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 53.4 | |||||
9-Day RSI | 50.58 | |||||
14-Day RSI | 49.87 | |||||
3-1 Month Momentum % | -32.35 | |||||
6-1 Month Momentum % | -51.42 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 36.01 | |||||
Quick Ratio | 36.01 | |||||
Cash Ratio | 35.96 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -48.26 | |||||
ROA % | -9.28 | |||||
ROIC % | -744.27 | |||||
ROC (Joel Greenblatt) % | -7038.32 | |||||
ROCE % | -15.11 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.45 | |||||
Price-to-Tangible-Book | 1.45 | |||||
EV-to-EBIT | -4.8 | |||||
EV-to-Forward-EBIT | -2.27 | |||||
EV-to-EBITDA | -4.8 | |||||
EV-to-FCF | -4.17 | |||||
Price-to-Net-Current-Asset-Value | 1.43 | |||||
Price-to-Net-Cash | 1.43 | |||||
Earnings Yield (Greenblatt) % | -20.83 | |||||
FCF Yield % | -6.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BCAX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bicara Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -2.836 | ||
Beta | - | ||
3-Year Sharpe Ratio | - | ||
3-Year Sortino Ratio | - | ||
Volatility % | - | ||
14-Day RSI | 49.87 | ||
14-Day ATR ($) | 1.2867 | ||
20-Day SMA ($) | 13.6745 | ||
12-1 Month Momentum % | - | ||
52-Week Range ($) | 11.1 - 28.09 | ||
Shares Outstanding (Mil) | 54.42 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Bicara Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Bicara Therapeutics Inc Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
Bicara Therapeutics Inc Frequently Asked Questions
What is Bicara Therapeutics Inc(BCAX)'s stock price today?
The current price of BCAX is $13.54. The 52 week high of BCAX is $28.09 and 52 week low is $11.10.
When is next earnings date of Bicara Therapeutics Inc(BCAX)?
The next earnings date of Bicara Therapeutics Inc(BCAX) is 2025-03-28 Est..
Does Bicara Therapeutics Inc(BCAX) pay dividends? If so, how much?
Bicara Therapeutics Inc(BCAX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |